nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

01.04.2014

Recent Advances in Transplantation for Primary Immune Deficiency Diseases: A Comprehensive Review

verfasst von: M. Teresa de la Morena, Robert P. Nelson Jr.

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Hematopoietic cell transplantation (HCT) is a curative therapeutic option for severe combined immunodeficiency (SCID), a group of diseases which otherwise carry life expectancies that are of limited duration and quality. Survival following HCT for SCID has improved from approximately 23 to 91 % over the last 40 years. Success with SCID prompted efforts to apply HCT to the therapeutic challenge of well over 20 molecularly defined primary immune deficiency diseases (PID). Such success is due to both early recognition of PIDs and advances in the field of transplantation. Such advances include high-resolution HLA DNA donor–recipient matching, expansion of donor sources, better tolerated conditioning, new antibiotics, and wider availability. International collaborative efforts have provided patients and caregivers information that permit better treatment decisions now, and direct clinicians and investigators to ensure progress in the future. Pioneers in screening for SCID have taken steps to correct the fundamental challenge to successful treatment, which is the rapid discovery and characterization of cases and offering the transplant option to an affected child early in life; blood spot testing for T and B cell receptor quantification is now available to a growing fraction of newborns. Organizations including the Primary Immune Deficiency Treatment Consortium in the USA, The European Society for Primary Immunodeficiency, the European Group for Blood and Marrow Transplantation, the Pediatric Blood and Marrow Transplant Consortium, the United States Immunodeficiency Network, the Immune Deficiency Foundation, and the Jeffrey Modell Foundation are contributing mightily to increase awareness and standardize optimal utilization to the benefit of patients. This review will update the allergist–immunologist concerning disease presentations, indications for transplantation, methodologies, conditioning regimens, and clinical outcomes for patients with PID for which timely HCT is critical.

Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA (1968) Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 2(7583):1366–1369PubMed

Thomas ED, Epstein RB (1965) Bone marrow transplantation in acute leukemia. Cancer Res 25(9):1521–1524PubMed

Nielsen H, Koch C, Muller-Berat N, Philip J (1973) Y chromatin as indicator of chimaerism following bone marrow transplantation in severe combined immunodeficiency. Scand J Immunol 2(4):327–331PubMed

Griscelli C, Durandy A, Ballet JJ, Prieur AM, Hors J (1977) T- and B-cell chimerism in two patients with severe combined immunodeficiency (SCID) after transplantation. Transplant Proc 9(1):171–175PubMed

Graw RG Jr, Rogentine GN Jr, Leventhal BG et al (1970) Graft-versus-host reaction complicating HL-A matched bone-marrow transplantation. Lancet 2(7682):1053–1055PubMed

Hong R, Bach FH (1970) Bone marrow transplantation. Aggravating factors in graft-versus-host disease. Transplantation 10(2):192–193PubMed

Kersey JH, Meuwissen HJ, Good RA (1971) Graft versus host reactions following transplantation of allogeneic hematopoietic cells. Hum Pathol 2(3):389–402PubMed

Bortin MM, Rimm AA, Saltzstein EC (1973) Graft versus leukemia: quantification of adoptive immunotherapy in murine leukemia. Science 179(75):811–813PubMed

O'Reilly RJ, Dupont B, Pahwa S et al (1977) Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor. N Engl J Med 297(24):1311–1318PubMed

10.

Horowitz MM, Gale RP, Sondel PM et al (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3):555–562PubMed

11.

Giralt S, Estey E, Albitar M et al (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89(12):4531–4536PubMed

12.

Khouri IF, Keating M, Korbling M et al (1998) Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16(8):2817–2824PubMed

13.

Slavin S, Nagler A, Naparstek E et al (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91(3):756–763PubMed

14.

Childs R, Clave E, Contentin N et al (1999) Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94(9):3234–3241PubMed

15.

Grigg A, Bardy P, Byron K, Seymour JF, Szer J (1999) Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. Bone Marrow Transplant 23(2):107–110PubMed

16.

Storb R, Yu C, Barnett T et al (1999) Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 94(3):1131–1136PubMed

17.

Sykes M, Preffer F, McAfee S et al (1999) Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 353(9166):1755–1759PubMed

18.

Thomas ED, Buckner CD, Banaji M et al (1977) One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 49:511–533PubMed

19.

Santos GW, Tutschka PJ, Brookmeyer R et al (1983) Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309:1347–1353PubMed

20.

Tutschka PJ, Copelan EA, Klein JP (1987) Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382–1388PubMed

21.

22.

23.

Giralt S, Thall PF, Khouri I et al (2001) Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97:631–637PubMed

24.

van Besien K, Artz A, Smith S et al (2005) Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23:5728–5738PubMed

25.

Storb R, Yu C, Sandmaier B et al (1999) Mixed hematopoietic chimerism after hematopoietic stem cell allografts. Transplant Proc 31:677–678PubMed

26.

27.

28.

Lowsky R, Takahashi T, Liu YP et al (2005) Protective conditioning for acute graft-versus-host disease. N Engl J Med 353:1321–1331PubMed

29.

Storb R, Yu C, Sandmaier B et al (1999) Mixed hematopoietic chimerism after hematopoietic stem cell allografts. Transplant Proc 31(1–2):677–678PubMed

30.

Satwani P, Harrison L, Morris E, Del Toro G, Cairo MS (2005) Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. Biol Blood Marrow Transplant 11(6):403–422PubMed

31.

Bacigalupo A (2002) Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplant 29(3):191–195PubMed

32.

Baron F, Storb R (2006) Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. Mol Ther 13(1):26–41PubMed

33.

Champlin R, Khouri I, Anderlini P et al (2003) Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncol (Williston Park) 17(1):94–100, discussion 103–107

34.

Lazarus HM, Rowe JM (2006) Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct. Leukemia 20(10):1673–1682PubMed

35.

Kim SH, Kee SY, Lee DG et al (2013) Infectious complications following allogeneic stem cell transplantation: reduced-intensity vs. myeloablative conditioning regimens. Transplant Infect Dis 15(1):49–59

36.

Diab KJ, Yu Z, Wood KL et al (2012) Comparison of pulmonary complications after nonmyeloablative and conventional allogeneic hematopoietic cell transplant. Biol Blood Marrow Transplant 18(12):1827–1834PubMed

37.

Booth C, Gilmour KC, Veys P et al (2011) X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 117(1):53–62PubMedCentralPubMed

38.

Amrolia P, Gaspar HB, Hassan A et al (2000) Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 96(4):1239–1246PubMed

39.

Katz F, Malcolm S, Strobel S, Finn A, Morgan G, Levinsky R (1990) The use of locus-specific minisatellite probes to check engraftment following allogeneic bone marrow transplantation for severe combined immunodeficiency disease. Bone Marrow Transplant 5(3):199–204PubMed

40.

Lau YL, Kwong YL, Lee AC et al (1995) Mixed chimerism following bone marrow transplantation for severe combined immunodeficiency: a study by DNA fingerprinting and simultaneous immunophenotyping and fluorescence in situ hybridisation. Bone Marrow Transplant 15(6):971–976PubMed

41.

Puck JM (2007) Population-based newborn screening for severe combined immunodeficiency: steps toward implementation. J Allergy Clin Immunol 120(4):760–768PubMed

42.

Douek DC, McFarland RD, Keiser PH et al (1998) Changes in thymic function with age and during the treatment of HIV infection. Nature 396(6712):690–695PubMed

43.

Clark PA, Lester T, Genet S et al (1995) Screening for mutations causing X-linked severe combined immunodeficiency in the IL-2R gamma chain gene by single-strand conformation polymorphism analysis. Hum Genet 96(4):427–432PubMed

44.

Chan K, Puck JM (2005) Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol 115(2):391–398PubMed

45.

Baker MW, Laessig RH, Katcher ML et al (2010) Implementing routine testing for severe combined immunodeficiency within Wisconsin's newborn screening program. Public Health Rep 125(Suppl 2):88–95PubMedCentralPubMed

46.

Comeau AM, Hale JE, Pai SY et al (2010) Guidelines for implementation of population-based newborn screening for severe combined immunodeficiency. J Inherit Metab Dis 33(Suppl 2):S273–281PubMed

47.

Gennery AR, Slatter MA, Grandin L, et al. (2010) Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 126(3):602–610.e601-611

48.

Buckley RH (2000) Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 343(18):1313–1324PubMed

49.

Reinherz EL, Geha R, Rappeport JM et al (1982) Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immunodeficiency. Proc Natl Acad Sci U S A 79(19):6047–6051PubMedCentralPubMed

50.

Reisner Y, Kapoor N, Kirkpatrick D et al (1983) Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 61(2):341–348PubMed

51.

Cowan MJ, Wara DW, Weintrub PS, Pabst H, Ammann AJ (1985) Haploidentical bone marrow transplantation for severe combined immunodeficiency disease using soybean agglutinin-negative, T-depleted marrow cells. J Clin Immunol 5(6):370–376PubMed

52.

Friedrich W, Goldmann SF, Ebell W et al (1985) Severe combined immunodeficiency: treatment by bone marrow transplantation in 15 infants using HLA-haploidentical donors. Eur J Pediatr 144(2):125–130PubMed

53.

Vossen JM, van Leeuwen JE, van Tol MJ et al (1993) Chimerism and immune reconstitution following allogeneic bone marrow transplantation for severe combined immunodeficiency disease. Immunodeficiency 4(1–4):311–313PubMed

54.

van Leeuwen JE, van Tol MJ, Joosten AM et al (1994) Relationship between patterns of engraftment in peripheral blood and immune reconstitution after allogeneic bone marrow transplantation for (severe) combined immunodeficiency. Blood 84(11):3936–3947PubMed

55.

Derry JM, Ochs HD, Francke U (1994) Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 79(5):following 922

56.

Perry GS 3rd, Spector BD, Schuman LM et al (1980) The Wiskott-Aldrich syndrome in the United States and Canada (1892–1979). J Pediatr 97(1):72–78PubMed

57.

Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia RM (2009) Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood 113(25):6288–6295PubMed

58.

Orange JS, Ramesh N, Remold-O'Donnell E et al (2002) Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci U S A 99(17):11351–11356PubMedCentralPubMed

59.

Ochs HD, Thrasher AJ (2006) The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 117(4):725–738, quiz 739PubMed

60.

Notarangelo LD, Mazza C, Giliani S et al (2002) Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia. Blood 99(6):2268–2269PubMed

61.

Ancliff PJ, Blundell MP, Cory GO et al (2006) Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood 108(7):2182–2189PubMed

62.

Zhu Q, Watanabe C, Liu T et al (1997) Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood 90(7):2680–2689PubMed

63.

Ochs HD, Filipovich AH, Veys P, Cowan MJ, Kapoor N (2009) Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant 15(1 Suppl):84–90PubMed

64.

Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA (1994) A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 125(6 Pt 1):876–885PubMed

65.

Imai K, Morio T, Zhu Y et al (2004) Clinical course of patients with WASP gene mutations. Blood 103(2):456–464PubMed

66.

Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM (1968) Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 2(7583):1364–1366PubMed

67.

Meuwissen HJ, Bortin MM, Bach FH et al (1984) Long-term survival after bone marrow transplantation: a 15-year follow-up report of a patient with Wiskott-Aldrich syndrome. J Pediatr 105(3):365–369PubMed

68.

Filipovich AH, Stone JV, Tomany SC et al (2001) Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 97(6):1598–1603PubMed

69.

Moratto D, Giliani S, Bonfim C et al (2011) Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980–2009: an international collaborative study. Blood 118(6):1675–1684PubMedCentralPubMed

70.

Mahlaoui N, Pellier I, Mignot C et al (2013) Characteristics and outcome of early-onset, severe forms of Wiskott-Aldrich syndrome. Blood 121(9):1510–1516PubMed

71.

Pai SY, DeMartiis D, Forino C et al (2006) Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant 38(10):671–679PubMed

72.

Kobayashi R, Ariga T, Nonoyama S et al (2006) Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Haematol 135(3):362–366PubMed

73.

Stepensky P, Krauss A, Goldstein G, et al. (2013) Impact of conditioning on outcome of hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome. J Pediatr Hematol Oncol. doi:10.1097/MPH.0b013e318279cbfc

74.

Ozsahin H, Le Deist F, Benkerrou M et al (1996) Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single center. J Pediatr 129(2):238–244PubMed

75.

Ozsahin H, Cavazzana-Calvo M, Notarangelo LD et al (2008) Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 111(1):439–445PubMed

76.

Notarangelo LD, Lanzi G, Peron S, Durandy A (2006) Defects of class-switch recombination. J Allergy Clin Immunol 117(4):855–864PubMed

77.

Winkelstein JA, Marino MC, Ochs H et al (2003) The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Med (Baltimore) 82(6):373–384

78.

Mensink EJ, Thompson A, Sandkuyl LA et al (1987) X-linked immunodeficiency with hyperimmunoglobulinemia M appears to be linked to the DXS42 restriction fragment length polymorphism locus. Hum Genet 76(1):96–99PubMed

79.

Padayachee M, Feighery C, Finn A et al (1992) Mapping of the X-linked form of hyper-IgM syndrome (HIGM1) to Xq26 by close linkage to HPRT. Genomics 14(2):551–553PubMed

80.

Allen RC, Armitage RJ, Conley ME et al (1993) CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 259(5097):990–993PubMed

81.

Aruffo A, Farrington M, Hollenbaugh D et al (1993) The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 72(2):291–300PubMed

82.

DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint BG (1993) CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 361(6412):541–543PubMed

83.

Fuleihan R, Ramesh N, Loh R et al (1993) Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci U S A 90(6):2170–2173PubMedCentralPubMed

84.

Korthauer U, Graf D, Mages HW et al (1993) Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 361(6412):539–541PubMed

85.

Miga A, Masters S, Gonzalez M, Noelle RJ (2000) The role of CD40-CD154 interactions in the regulation of cell mediated immunity. Immunol Invest 29(2):111–114PubMed

86.

Etzioni A, Ochs HD (2004) The hyper IgM syndrome—an evolving story. Pediatr Res 56(4):519–525PubMed

87.

Noelle RJ (1995) The role of gp39 (CD40L) in immunity. Clin Immunol Immunopathol 76(3 Pt 2):S203–S207PubMed

88.

Jain A, Atkinson TP, Lipsky PE, Slater JE, Nelson DL, Strober W (1999) Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. J Clin Invest 103(8):1151–1158PubMedCentralPubMed

89.

Levy J, Espanol-Boren T, Thomas C et al (1997) Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 131(1 Pt 1):47–54PubMed

90.

Cabral-Marques O, Schimke LF, Pereira PV et al (2012) Expanding the clinical and genetic spectrum of human CD40L deficiency: the occurrence of paracoccidioidomycosis and other unusual infections in Brazilian patients. J Clin Immunol 32(2):212–220PubMed

91.

Notarangelo LD, Lanzi G, Toniati P, Giliani S (2007) Immunodeficiencies due to defects of class-switch recombination. Immunol Res 38(1–3):68–77PubMed

92.

Wolska-Kusnierz B, Bajer A, Caccio S et al (2007) Cryptosporidium infection in patients with primary immunodeficiencies. J Pediatr Gastroenterol Nutr 45(4):458–464PubMed

93.

Jesus AA, Duarte AJ, Oliveira JB (2008) Autoimmunity in hyper-IgM syndrome. J Clin Immunol 28(Suppl 1):S62–66PubMed

94.

Hayward AR, Levy J, Facchetti F et al (1997) Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol 158(2):977–983PubMed

95.

Banatvala N, Davies J, Kanariou M, Strobel S, Levinsky R, Morgan G (1994) Hypogammaglobulinaemia associated with normal or increased IgM (the hyper IgM syndrome): a case series review. Arch Dis Child 71(2):150–152PubMedCentralPubMed

96.

Thomas C, de Saint BG, Le Deist F et al (1995) Brief report: correction of X-linked hyper-IgM syndrome by allogeneic bone marrow transplantation. N Engl J Med 333(7):426–429PubMed

97.

Bordigoni P, Auburtin B, Carret AS et al (1998) Bone marrow transplantation as treatment for X-linked immunodeficiency with hyper-IgM. Bone Marrow Transplant 22(11):1111–1114PubMed

98.

Hadzic N, Pagliuca A, Rela M et al (2000) Correction of the hyper-IgM syndrome after liver and bone marrow transplantation. N Engl J Med 342(5):320–324PubMed

99.

Duplantier JE, Seyama K, Day NK et al (2001) Immunologic reconstitution following bone marrow transplantation for X-linked hyper IgM syndrome. Clin Immunol 98(3):313–318PubMed

100.

Khawaja K, Gennery AR, Flood TJ, Abinun M, Cant AJ (2001) Bone marrow transplantation for CD40 ligand deficiency: a single centre experience. Arch Dis Child 84(6):508–511PubMedCentralPubMed

101.

Tomizawa D, Imai K, Ito S et al (2004) Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience. Am J Hematol 76(1):33–39PubMed

102.

Jacobsohn DA, Emerick KM, Scholl P et al (2004) Nonmyeloablative hematopoietic stem cell transplant for X-linked hyper-immunoglobulin m syndrome with cholangiopathy. Pediatrics 113(2):e122–127PubMed

103.

Tsuji Y, Imai K, Kajiwara M et al (2006) Hematopoietic stem cell transplantation for 30 patients with primary immunodeficiency diseases: 20 years experience of a single team. Bone Marrow Transplant 37(5):469–477PubMed

104.

Kikuta A, Ito M, Mochizuki K et al (2006) Nonmyeloablative stem cell transplantation for nonmalignant diseases in children with severe organ dysfunction. Bone Marrow Transplant 38(10):665–669PubMed

105.

Sato T, Kobayashi R, Toita N et al (2007) Stem cell transplantation in primary immunodeficiency disease patients. Pediatr Int 49(6):795–800PubMed

106.

Gennery AR, Khawaja K, Veys P et al (2004) Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993–2002. Blood 103(3):1152–1157PubMed

107.

Jain A, Kovacs JA, Nelson DL et al (2011) Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand. Blood 118(14):3811–3817PubMedCentralPubMed

108.

Winkelstein JA, Marino MC, Johnston RB Jr et al (2000) Chronic granulomatous disease. Report on a national registry of 368 patients. Med (Baltimore) 79(3):155–169

109.

Martire B, Rondelli R, Soresina A et al (2008) Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol 126(2):155–164PubMed

110.

Kobayashi S, Murayama S, Takanashi S et al (2008) Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. Eur J Pediatr 167(12):1389–1394PubMed

111.

Gallin JI, Alling DW, Malech HL et al (2003) Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 348(24):2416–2422PubMed

112.

Kang EM, Marciano BE, DeRavin S, Zarember KA, Holland SM, Malech HL (2011) Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. J Allergy Clin Immunol 127(6):1319–1326, quiz 1327–1318PubMedCentralPubMed

113.

Jones LB, McGrogan P, Flood TJ et al (2008) Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol 152(2):211–218PubMedCentralPubMed

114.

Cole T, McKendrick F, Titman P et al (2013) Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant. J Clin Immunol 33(1):8–13PubMed

115.

Di Bartolomeo P, Di Girolamo G, Angrilli F et al (1989) Reconstitution of normal neutrophil function in chronic granulomatous disease by bone marrow transplantation. Bone Marrow Transplant 4(6):695–700PubMed

116.

Schettini F, De Mattia D, Manzionna MM et al (1987) Bone marrow transplantation for chronic granulomatous disease associated with cytochrome B deficiency. Pediatr Hematol Oncol 4(3):277–279PubMed

117.

Horwitz ME, Barrett AJ, Brown MR et al (2001) Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 344(12):881–888PubMed

118.

Seger RA, Gungor T, Belohradsky BH et al (2002) Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985–2000. Blood 100(13):4344–4350PubMed

119.

Kuhns DB, Alvord WG, Heller T et al (2010) Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 363(27):2600–2610PubMedCentralPubMed

120.

Feld JJ, Hussain N, Wright EC et al (2008) Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. Gastroenterology 134(7):1917–1926PubMedCentralPubMed

121.

Soncini E, Slatter MA, Jones LB et al (2009) Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol 145(1):73–83PubMed

122.

Purtilo DT, Grierson HL, Davis JR, Okano M (1991) The X-linked lymphoproliferative disease: from autopsy toward cloning the gene 1975–1990. Pediatr Pathol/ AffWith the Inter Paediatr Pathol Assoc 11(5):685–710

123.

Coffey AJ, Brooksbank RA, Brandau O et al (1998) Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 20(2):129–135PubMed

124.

Seemayer TA, Gross TG, Egeler RM et al (1995) X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res 38(4):471–478PubMed

125.

Hoffmann T, Heilmann C, Madsen HO, Vindelov L, Schmiegelow K (1998) Matched unrelated allogeneic bone marrow transplantation for recurrent malignant lymphoma in a patient with X-linked lymphoproliferative disease (XLP). Bone Marrow Transplant 22(6):603–604PubMed

126.

Gross TG, Filipovich AH, Conley ME et al (1996) Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): report from the XLP registry. Bone Marrow Transplant 17(5):741–744PubMed

127.

Lankester AC, Visser LF, Hartwig NG et al (2005) Allogeneic stem cell transplantation in X-linked lymphoproliferative disease: two cases in one family and review of the literature. Bone Marrow Transplant 36(2):99–105PubMed

128.

Janka GE (2012) Familial and acquired hemophagocytic lymphohistiocytosis. Annual Revof Med 63:233–246

129.

Henter JI, Horne A, Arico M et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124–131PubMed

130.

Janka GE (1983) Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr 140(3):221–230PubMed

131.

Henter JI, Arico M, Elinder G, Imashuku S, Janka G (1998) Familial hemophagocytic lymphohistiocytosis. Primary hemophagocytic lymphohistiocytosis. Hematol/Oncol Clinics of North Am 12(2):417–433

132.

Trottestam H, Horne A, Arico M et al (2011) Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood 118(17):4577–4584PubMedCentralPubMed

133.

Chatila TA, Blaeser F, Ho N et al (2000) JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 106(12):R75–R81PubMedCentralPubMed

134.

Powell BR, Buist NR, Stenzel P (1982) An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. J Pediatr 100(5):731–737PubMed

135.

Taddio A, Faleschini E, Valencic E et al (2007) Medium-term survival without haematopoietic stem cell transplantation in a case of IPEX: insights into nutritional and immunosuppressive therapy. Eur J Pediatr 166(11):1195–1197PubMed

136.

Rao A, Kamani N, Filipovich A et al (2007) Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood 109(1):383–385PubMed

137.

Baud O, Goulet O, Canioni D et al (2001) Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 344(23):1758–1762PubMed

138.

Burroughs LM, Torgerson TR, Storb R et al (2010) Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. J Allergy Clin Immunol 126(5):1000–1005PubMedCentralPubMed

139.

Kasow KA, Morales-Tirado VM, Wichlan D et al (2011) Therapeutic in vivo selection of thymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX. Clin Immunol 141(2):169–176PubMedCentralPubMed

Titel: Recent Advances in Transplantation for Primary Immune Deficiency Diseases: A Comprehensive Review
verfasst von: M. Teresa de la Morena
Robert P. Nelson Jr.
Publikationsdatum: 01.04.2014
Verlag: Springer US
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 2/2014
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-013-8379-6

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Recent Advances in Transplantation for Primary Immune Deficiency Diseases: A Comprehensive Review

Abstract

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Laboratory Diagnosis of Primary Immunodeficiencies

Skin Manifestations of Primary Immune Deficiency

Historical Perspectives in the Diagnosis and Treatment of Primary Immune Deficiencies

Primary Selective IgM Deficiency: An Ignored Immunodeficiency

New Genetic Discoveries and Primary Immune Deficiencies

The Hyper IgM Syndromes

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update HNO